Global Wilson's Disease Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Wilson's Disease Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Wilson’s disease is also known as progressive lenticular degeneration and hepatolenticular degeneration that causes copper poisoning in the body. Copper is a necessary element for cellular functions; however, excessive copper is extremely toxic and can cause permanent damage to cellular functions of body. Wilson’s disease is caused by excessive deposition of copper in the body. Generally, copper is released into bile from the diet is cleaned out by the liver, flowing out of the body from the gastrointestinal tract. Wilson’s disease occurs due to excessive deposition of copper in the brain, liver, and other tissues of the body. According to the American Association for the Study of Liver Diseases, Wilson’s disease occurs worldwide with prevalence of approximately 30 individuals affected per million.
Due to the COVID-19 pandemic, the global Wilson's Disease Drugs market size was US$ 204.1 million in 2022 and is forecast to a readjusted size of US$ 307.4 million by 2034 with a CAGR of 5.9% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Hepatic accounting for % of the Wilson's Disease Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Wilson's Disease Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Wilson's Disease Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Wilson's Disease Drugs market. Readers of the report can become informed about current and future trends of the global Wilson's Disease Drugs market and how they will impact market growth during the forecast period.
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Wilson's Disease Drugs in global and regional level.
Chapter 3Detailed analysis of Wilson's Disease Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Wilson's Disease Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Wilson's Disease Drugs market size was US$ 204.1 million in 2022 and is forecast to a readjusted size of US$ 307.4 million by 2034 with a CAGR of 5.9% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Hepatic accounting for % of the Wilson's Disease Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Wilson's Disease Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Wilson's Disease Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Wilson's Disease Drugs market. Readers of the report can become informed about current and future trends of the global Wilson's Disease Drugs market and how they will impact market growth during the forecast period.
By Company
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Segment by Application
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Wilson's Disease Drugs in global and regional level.
Chapter 3Detailed analysis of Wilson's Disease Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Wilson's Disease Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices